Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.67 +0.5%	$3.32	$2.70 ▼ $4.72	$703.54M	0.86	872,375 shs	589,277 shs
CRBU Caribou Biosciences	$1.94 -2.0%	$1.78	$0.66 ▼ $3.00	$180.65M	2.55	1.33 million shs	958,705 shs
GHRS GH Research	$13.84 +1.5%	$13.95	$6.00 ▼ $20.50	$720.10M	0.98	333,691 shs	96,917 shs
KALV KalVista Pharmaceuticals	$13.51 -0.6%	$13.45	$7.30 ▼ $16.32	$680.09M	0.05	777,887 shs	416,522 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	+4.58%	+8.96%	+6.10%	-5.68%
CRBU Caribou Biosciences	-1.00%	+10.00%	-13.54%	+70.69%	-8.33%
GHRS GH Research	+1.79%	+6.65%	-9.01%	+12.83%	+20.41%
KALV KalVista Pharmaceuticals	+3.27%	+5.27%	+0.15%	+14.30%	+7.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.7057 of 5 stars	3.5	1.0	0.0	3.6	2.5	0.6
CRBU Caribou Biosciences	2.6607 of 5 stars	3.5	5.0	0.0	1.5	1.7	0.0
GHRS GH Research	2.2898 of 5 stars	3.4	3.0	0.0	1.6	2.5	0.0
KALV KalVista Pharmaceuticals	3.701 of 5 stars	3.6	1.0	4.4	2.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	49.86% Upside
CRBU Caribou Biosciences	3.00	Buy	$6.67	243.64% Upside
GHRS GH Research	2.88	Moderate Buy	$32.00	131.21% Upside
KALV KalVista Pharmaceuticals	3.11	Buy	$26.29	94.56% Upside

Current Analyst Ratings Breakdown

Latest CRBU, ABUS, GHRS, and KALV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2025	GHRS GH Research	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/8/2025	KALV KalVista Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$19.00 ➝ $27.00
7/8/2025	KALV KalVista Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $27.00
7/7/2025	KALV KalVista Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$18.00 ➝ $20.00
6/24/2025	GHRS GH Research	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$39.00
6/4/2025	GHRS GH Research	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$15.42M	45.64	N/A	N/A	$0.43 per share	8.53
CRBU Caribou Biosciences	$9.99M	18.08	N/A	N/A	$1.78 per share	1.09
GHRS GH Research	N/A	N/A	N/A	N/A	$5.83 per share	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	$1.92 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	11/5/2025 (Estimated)
CRBU Caribou Biosciences	-$149.10M	-$1.78	N/A	N/A	N/A	-1,800.93%	-62.35%	-49.65%	11/5/2025 (Estimated)
GHRS GH Research	-$38.96M	-$0.74	N/A	N/A	N/A	N/A	-16.71%	-16.06%	9/2/2025 (Estimated)
KALV KalVista Pharmaceuticals	-$183.44M	-$3.69	N/A	N/A	N/A	N/A	-134.07%	-82.65%	9/4/2025 (Estimated)

Latest CRBU, ABUS, GHRS, and KALV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2025	Q1 2026	KALV KalVista Pharmaceuticals	-$0.91	N/A	N/A	N/A	$1.97 million	N/A
9/2/2025	Q2 2025	GHRS GH Research	-$0.22	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	CRBU Caribou Biosciences	-$0.40	-$0.35	+$0.05	-$0.58	$1.64 million	$2.67 million
8/7/2025	Q2 2025	GHRS GH Research	-$0.22	-$0.15	+$0.07	-$0.15	N/A	N/A
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million
7/10/2025	Q4 2025	KALV KalVista Pharmaceuticals	-$0.83	-$3.69	-$2.86	-$0.99	$4.20 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
GHRS GH Research	N/A	N/A	N/A	N/A	N/A
KALV KalVista Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
CRBU Caribou Biosciences	N/A	6.66	6.66
GHRS GH Research	N/A	29.49	29.49
KALV KalVista Pharmaceuticals	N/A	5.35	5.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
CRBU Caribou Biosciences	77.51%
GHRS GH Research	56.90%
KALV KalVista Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
CRBU Caribou Biosciences	8.28%
GHRS GH Research	41.60%
KALV KalVista Pharmaceuticals	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
CRBU Caribou Biosciences	100	93.12 million	85.41 million	Optionable
GHRS GH Research	10	52.03 million	30.38 million	Optionable
KALV KalVista Pharmaceuticals	100	50.34 million	48.18 million	Optionable

CRBU, ABUS, GHRS, and KALV Headlines

Recent News About These Companies

Nicole Sweeny Sells 1,864 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

August 28 at 8:17 AM | marketbeat.com

KalVista Pharmaceuticals Stock Sees RS Rating Rise To 82

August 28 at 2:51 AM | msn.com

Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 2,942 Shares of Stock

August 27 at 8:58 PM | marketbeat.com

KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,940 Shares

August 27 at 8:35 PM | marketbeat.com

KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,480 Shares

August 27 at 7:37 AM | insidertrades.com

KalVista Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2025

August 27 at 7:11 AM | mms.businesswire.com

Stonepine Capital Management LLC Acquires New Holdings in KalVista Pharmaceuticals, Inc. $KALV

August 26 at 7:38 AM | marketbeat.com

Paul Audhya Sells 2,942 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

August 26 at 5:07 AM | insidertrades.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Consensus Recommendation of "Buy" from Brokerages

August 20, 2025 | marketbeat.com

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Average Rating of "Buy" by Brokerages

August 19, 2025 | americanbankingnews.com

KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Up 3.7% - Time to Buy?

August 16, 2025 | marketbeat.com

Stocks To Watch: KalVista Pharmaceuticals Sees Relative Strength Rating Rise To 82

August 15, 2025 | msn.com

KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50-Day Moving Average - Time to Sell?

August 14, 2025 | marketbeat.com

Stocks With Rising Relative Strength: KalVista Pharmaceuticals

August 12, 2025 | msn.com

Metagenomi Appoints Laurence Reid, PhD to its Board of Directors

August 11, 2025 | globenewswire.com

KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union

August 11, 2025 | finance.yahoo.com

Kaken strengthens late-stage HAE portfolio with $32M deal for rights to Astria’s navenibart in Japan

August 7, 2025 | fiercebiotech.comF

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 4, 2025 | businesswire.com

EMA Backs First Oral Treatment for Hereditary Angioedema

July 29, 2025 | medscape.comM

KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency

July 29, 2025 | msn.com

KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade)

July 27, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU, ABUS, GHRS, and KALV Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.67 +0.02 (+0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$3.66 0.00 (-0.14%)

As of 04:50 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Caribou Biosciences NASDAQ:CRBU

$1.94 -0.04 (-2.02%)

Closing price 04:00 PM Eastern

Extended Trading

$1.96 +0.03 (+1.29%)

As of 05:46 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

GH Research NASDAQ:GHRS

$13.84 +0.21 (+1.54%)

Closing price 04:00 PM Eastern

Extended Trading

$13.72 -0.12 (-0.87%)

As of 05:05 PM Eastern

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

KalVista Pharmaceuticals NASDAQ:KALV

$13.51 -0.08 (-0.59%)

Closing price 04:00 PM Eastern

Extended Trading

$13.60 +0.09 (+0.67%)

As of 04:40 PM Eastern

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time